NovoCure Ltd
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NVCR$12.53-5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 7A.
NovoCure Limited
Index to consolidated financial statements
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 1281) | 66 |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | 69 |
| Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021 | 71 |
| Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2023, 2022 and 2021 | 72 |
| Statements of Changes in Shareholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | 73 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | 74 |
| Notes to Consolidated Financial Statements | 76 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.